BR112012012108A2 - composição farmacêutica compreendendo propofol - Google Patents
composição farmacêutica compreendendo propofolInfo
- Publication number
- BR112012012108A2 BR112012012108A2 BR112012012108A BR112012012108A BR112012012108A2 BR 112012012108 A2 BR112012012108 A2 BR 112012012108A2 BR 112012012108 A BR112012012108 A BR 112012012108A BR 112012012108 A BR112012012108 A BR 112012012108A BR 112012012108 A2 BR112012012108 A2 BR 112012012108A2
- Authority
- BR
- Brazil
- Prior art keywords
- propofol
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C19/00—Acyclic saturated compounds containing halogen atoms
- C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09014548A EP2332525A1 (en) | 2009-11-23 | 2009-11-23 | Pharmaceutical composition comprising propofol |
| PCT/EP2010/067938 WO2011061332A1 (en) | 2009-11-23 | 2010-11-22 | Pharmaceutical composition comprising propofol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012012108A2 true BR112012012108A2 (pt) | 2016-04-05 |
Family
ID=41694756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012012108A BR112012012108A2 (pt) | 2009-11-23 | 2010-11-22 | composição farmacêutica compreendendo propofol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8796340B2 (enExample) |
| EP (2) | EP2332525A1 (enExample) |
| JP (1) | JP5707009B2 (enExample) |
| KR (1) | KR20120104262A (enExample) |
| CN (1) | CN102753159B (enExample) |
| AU (1) | AU2010320823B2 (enExample) |
| BR (1) | BR112012012108A2 (enExample) |
| CA (1) | CA2776855C (enExample) |
| ES (1) | ES2450423T3 (enExample) |
| IN (1) | IN2012DN03130A (enExample) |
| MX (1) | MX2012005881A (enExample) |
| WO (1) | WO2011061332A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
| PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
| GB201116271D0 (en) | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
| AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| TR201812013T4 (tr) * | 2012-09-12 | 2018-09-21 | Novaliq Gmbh | Göz yikama bi̇leşi̇mleri̇. |
| CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| US20180022698A1 (en) | 2014-10-16 | 2018-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| MY206642A (en) | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| AU2020340561A1 (en) | 2019-09-06 | 2022-03-31 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| EP3912622A1 (en) | 2020-05-19 | 2021-11-24 | tesa Labtec GmbH | Oral film for safe administration of api |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496537A (en) * | 1995-03-23 | 1996-03-05 | Henry; Richard A. | Propofol hydrofluorocarbon propellant formulations |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| WO2000054588A1 (en) * | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| GB0124071D0 (en) * | 2001-10-08 | 2001-11-28 | Kbig Ltd | Improvement in the administration of high boiling point aneasthetics |
| WO2005067517A2 (en) * | 2004-01-02 | 2005-07-28 | Wisconsin Alumni Research Foundation | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| DE102004030044A1 (de) | 2004-06-22 | 2006-01-12 | Birken Gmbh | Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels |
| JP5569899B2 (ja) * | 2006-11-28 | 2014-08-13 | ウィスコンシン・アラムナイ・リサーチ・ファウンデーション | 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション |
| PL2110126T3 (pl) * | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
-
2009
- 2009-11-23 EP EP09014548A patent/EP2332525A1/en not_active Withdrawn
-
2010
- 2010-11-22 MX MX2012005881A patent/MX2012005881A/es not_active Application Discontinuation
- 2010-11-22 US US13/511,184 patent/US8796340B2/en active Active
- 2010-11-22 ES ES10778677.4T patent/ES2450423T3/es active Active
- 2010-11-22 JP JP2012539355A patent/JP5707009B2/ja active Active
- 2010-11-22 KR KR1020127016348A patent/KR20120104262A/ko not_active Withdrawn
- 2010-11-22 WO PCT/EP2010/067938 patent/WO2011061332A1/en not_active Ceased
- 2010-11-22 CN CN201080052400.7A patent/CN102753159B/zh active Active
- 2010-11-22 AU AU2010320823A patent/AU2010320823B2/en active Active
- 2010-11-22 BR BR112012012108A patent/BR112012012108A2/pt not_active Application Discontinuation
- 2010-11-22 CA CA2776855A patent/CA2776855C/en active Active
- 2010-11-22 IN IN3130DEN2012 patent/IN2012DN03130A/en unknown
- 2010-11-22 EP EP10778677.4A patent/EP2503999B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2332525A1 (en) | 2011-06-15 |
| IN2012DN03130A (enExample) | 2015-09-18 |
| US20120238639A1 (en) | 2012-09-20 |
| MX2012005881A (es) | 2012-06-19 |
| AU2010320823A1 (en) | 2012-07-12 |
| CN102753159A (zh) | 2012-10-24 |
| EP2503999B1 (en) | 2013-12-25 |
| WO2011061332A1 (en) | 2011-05-26 |
| CA2776855C (en) | 2017-10-24 |
| ES2450423T3 (es) | 2014-03-24 |
| AU2010320823B2 (en) | 2014-06-26 |
| CA2776855A1 (en) | 2011-05-26 |
| EP2503999A1 (en) | 2012-10-03 |
| KR20120104262A (ko) | 2012-09-20 |
| US8796340B2 (en) | 2014-08-05 |
| CN102753159B (zh) | 2014-03-12 |
| JP2013511496A (ja) | 2013-04-04 |
| JP5707009B2 (ja) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012012108A2 (pt) | composição farmacêutica compreendendo propofol | |
| DK3097925T3 (da) | Farmaceutisk sammensætning | |
| BRPI1004940A2 (pt) | composição farmacêutica | |
| SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
| SMT201700008B (it) | Composizione farmaceutica | |
| BRPI1012539A2 (pt) | composições farmacêuticas | |
| SMT201600350B (it) | Composizioni farmaceutiche | |
| LT3061445T (lt) | Labai koncentruotos farmacinės kompozicijos | |
| SMT201600307B (it) | Composizione liposomiale | |
| BRPI1015939A2 (pt) | composição farmacêutica | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| BRPI1013588A2 (pt) | composição | |
| EP2451274A4 (en) | Pharmaceutical compositions | |
| BRPI1015474A2 (pt) | composição | |
| IT1394400B1 (it) | Composizioni farmaceutiche | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
| EE201300005A (et) | Ravimkoostis | |
| EP2236149A4 (en) | MEDICAL COMPOSITION | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
| CO6801722A2 (es) | Composiciones farmacéuticas | |
| BRPI1005290A2 (pt) | composição | |
| EP2394634A4 (en) | COMPOSITION CONTAINING HESPERIDINE | |
| BR112012003149A2 (pt) | composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |